![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Molecular Pharmacology, Vol 12, 900-910, Copyright © 1976 by the American Society for Pharmacology and Experimental Therapeutics
1 Laboratory of Chemistry, National Instiute of Arthritis, Metabolism, and Digestive Diseases, National
Institutes of Health, Bethesda, Maryland 20014
A new class of inhibitor of phosphodiesterases is represented by 4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK 62711). This compound enhances the magnitude of accumulations of cyclic 3',5'-AMP elicited by norepinephrine, isoproterenol, histamine, and adenosine in rat cerebral cortical slices and by veratridine in rat cerebellar slices and, in addition, increases basal levels of cyclic AMP in both cortical and cerebellar slices. Increases in intracellular levels of cyclic AMP in brain slices elicited by ZK 62711 do not appear to involve enhanced "release" of adenosine, since both basal and norepinephrine-elicited accumulations of cyclic AMP are increased by ZK 62711 in the presence of exogenous adenosine deaminase. ZK 62711 has little effect on levels of cyclic GMP in cortical or cerebellar slices. In rat cerebral homogenates ZK 62711 inhibits soluble and particulate cyclic AMP phosphodiesterases but is less potent with respect to cyclic GMP phosphodiesterases. At low concentrations it is 100 times more potent than a structurally related phosphodiesterase inhibitor, Ro 20-1724, with respect to the calcium-dependent cyclic AMP phosphodiesterase, and in brain slices it is similarly 100 times more potent in enhancing accumulations of cyclic AMP elicited by norepinephrine.
Submitted on April 26, 1976
This article has been cited by other articles:
|
|
 |
|
  A. T. Bender and J. A. Beavo Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use Pharmacol. Rev., September 1, 2006; 58(3): 488 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhao, H.-T. Zhang, and J. M. O'Donnell Inhibitor Binding to Type 4 Phosphodiesterase (PDE4) Assessed Using [3H]Piclamilast and [3H]Rolipram J. Pharmacol. Exp. Ther., May 1, 2003; 305(2): 565 - 572. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. De Arcangelis, D. Coletti, M. Conti, M. Lagarde, M. Molinaro, S. Adamo, G. Nemoz, and F. Naro IGF-I-induced Differentiation of L6 Myogenic Cells Requires the Activity of cAMP-Phosphodiesterase Mol. Biol. Cell, April 1, 2003; 14(4): 1392 - 1404. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Naro, C. Sette, E. Vicini, V. De Arcangelis, M. Grange, M. Conti, M. Lagarde, M. Molinaro, S. Adamo, and G. Némoz Involvement of Type 4 cAMP-Phosphodiesterase in the Myogenic Differentiation of L6 Cells Mol. Biol. Cell, December 1, 1999; 10(12): 4355 - 4367. [Abstract] [Full Text]
|
|
|
|
|
|
D. C. Underwood, S. Bochnowicz, R. R. Osborn, C. J. Kotzer, M. A. Luttmann, D. W.P. Hay, P. D. Gorycki, S. B. Christensen, and T. J. Torphy Antiasthmatic Activity of the Second-Generation Phosphodiesterase 4 (PDE4) Inhibitor SB 207499 (Ariflo) in the Guinea Pig J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 988 - 995. [Abstract] [Full Text]
|
|
|
|
 |
|
 S.-L. C. Jin, T. Bushnik, L. Lan, and M. Conti Subcellular Localization of Rolipram-sensitive, cAMP-specific Phosphodiesterases. DIFFERENTIAL TARGETING AND ACTIVATION OF THE SPLICING VARIANTS DERIVED FROM THE PDE4D GENE J. Biol. Chem., July 31, 1998; 273(31): 19672 - 19678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.W.D. Rowlands, T. Silverstone, and J.C. Cookson A double-blind placebo-controlled study of rolipram in depressed in-patients J Psychopharmacol, January 1, 1989; 3(3): 169 - 174. [Abstract] [PDF]
|
|
|
|
|
|
S.A. Checkley, F. Winton, T. Corn, C. Franey, and J. Arendt Effects of a phosphodiesterase inhibitor (Rolipram) on the urinary excretion of 6-sulphatoxy melatonin in man J Psychopharmacol, January 1, 1987; 1(1): 20 - 22. [Abstract] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
